Bao Z, Liu X, Liu Y, Liu H, Zhao K
Yes, the GLP-1 released from our intestinal cells is rapidly degraded, leading to low systemic levels, but its effects appear to be mediated by vagus nerve stimulation
GLP-1 agonist users may continue at maintenance doses long-term under medical supervision
The ACHIEVE program for type 2 diabetes includes ACHIEVE-1 (NCT05971940, completed), ACHIEVE-2 (NCT06192108, completed), ACHIEVE-3 (NCT06045221, completed), ACHIEVE-4 (NCT05803421), ACHIEVE-5 (NCT06109311, completed), and ACHIEVE-J (NCT06010004, Japan-specific)
Patients with pre-existing medical conditions need closer monitoring
Summary & Key Takeaways GHK-Cu is a naturally occurring copper-binding tripeptide with proven tissue-repair and anti-inflammatory actions